国产雷帕霉素与依维莫司或佐他莫司药物洗脱支架治疗冠状动脉左主干开口及体部病变效果比较(4)
[12]Levine GN，Bates ER，Blankenship JC，et al.2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions[J].J Am Coll Cardiol，2011，58(24)：e44-e122.
[13]Kandzari DE，Mauri L，Popma JJ，et al.Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR Ⅲ(A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)[J].JACC Cardiovasc Interv，2011，4(5)：543-550.
[14]Wijns W，Steg PG，Mauri L，et al.Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent：4-year results of the PROTECT randomized trial[J].Eur Heart J，2014，35(40)：2812-2820.
[15]Fan J，Du H，Yin Y，et al.Efficacy and safety of zotarolimus-eluting stents compared with sirolimus-eluting stents in patients undergoing percutaneous coronary interventions-a meta-analysis of randomized controlled trials[J].Int J Cardiol，2013，167(5)：2126-2133.
[16]Pan DR，Zhu H，Hu ZY，et al.Cobalt chromium-based biodegradable polymer sirolimus-eluting stent：rationale，evidence and clinical experience[J].Minerva Cardioangiol，2015，63(5)：411-426.
[17]Gao RL，Xu B，Lansky AJ，et al.A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer evero limus-eluting stent：clinical and angiographic follow-up of the TARGET Ⅰ trial[J].EuroIntervention，2013，9(1)：75-83.
(收稿日期：2019-02-13 本文編辑：许俊琴), http://www.100md.com(王志超 李小龙 陈宇)
[13]Kandzari DE，Mauri L，Popma JJ，et al.Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR Ⅲ(A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)[J].JACC Cardiovasc Interv，2011，4(5)：543-550.
[14]Wijns W，Steg PG，Mauri L，et al.Endeavour zotarolimus-eluting stent reduces stent thrombosis and improves clinical outcomes compared with cypher sirolimus-eluting stent：4-year results of the PROTECT randomized trial[J].Eur Heart J，2014，35(40)：2812-2820.
[15]Fan J，Du H，Yin Y，et al.Efficacy and safety of zotarolimus-eluting stents compared with sirolimus-eluting stents in patients undergoing percutaneous coronary interventions-a meta-analysis of randomized controlled trials[J].Int J Cardiol，2013，167(5)：2126-2133.
[16]Pan DR，Zhu H，Hu ZY，et al.Cobalt chromium-based biodegradable polymer sirolimus-eluting stent：rationale，evidence and clinical experience[J].Minerva Cardioangiol，2015，63(5)：411-426.
[17]Gao RL，Xu B，Lansky AJ，et al.A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer evero limus-eluting stent：clinical and angiographic follow-up of the TARGET Ⅰ trial[J].EuroIntervention，2013，9(1)：75-83.
(收稿日期：2019-02-13 本文編辑：许俊琴), http://www.100md.com(王志超 李小龙 陈宇)